BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development
SAN DIEGO — The U.S. Food and Drug Administration (FDA) is undergoing a significant cultural and operational transformation amid growing U.S.–China competition in biotechnology. This shift is prompting a reevaluation of regulatory frameworks, particularly concerning rare diseases, and emphasizes the need for integrating patient perspectives into the drug development continuum. These themes were central to…









